Key elements in adverse drug interaction safety signals: An assessment of individual case safety reports

Drug Safety

Volumn 36, Issue 1, 2013, Pages 63-70

  Strandell, Johanna ^a,b   Norén, G Niklas ^a   Hägg, Staffan ^b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; AZITHROMYCIN; GLUCOSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PHENPROCOUMON; WARFARIN;

ARTICLE; DATA BASE; DRUG INTERACTION; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMATION RETRIEVAL; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84876587410     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-012-0003-9     Document Type: Article

References (20)

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-9.
2. Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf. 2002;11(1):65-72.
3. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ. 2000;320(7241):1036.
4. Schneeweiss S, Hasford J, Gottler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285-91.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15-9.
7. Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667-75.
8. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674-80.
9. Strandell J, Caster O, Bate A, et al. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34(3):253-66.
10. Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409-19.
11. Edwards IR, Olsson S. The WHO international drug monitoring programme. In: Aronson JK, editor. Side effects of drugs annual 25. Amsterdam: Elsevier Science B.V.; 2002. p. 589-598.
12. Yue QY, Strandell J, Myrberg O. Concomitant use of glucosamine potentiates the effect of warfarin (abstract). Drug Saf. 2006;29(10):934.
13. Strandell J, Bate A, Hägg S, et al. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009;68(3):427-34.
14. Netherlands Pharmacovigilance Centre, Lareb. Signal (serial on the internet). 2009. Available from http://www.lareb.nl/LarebCorporateWebsite/media/ publicaties/kwb-2009-3-omepr.pdf. Accessed 2 Nov 2012.
15. The electronic Medicines Compendium, Datapharm Communications Ltd. Electronic version. 2008. Available from URL: http://www.medicines.org.uk/. Accessed Oct 2008.
16. DrugDex. 2008. Available from URL: http://www.thomsonhc.com. Accessed Oct 2008.
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
18. Strandell J, Bate A, Lindquist M, et al. Database SFINX. Drug-drug interactions: a preventable patient safety issue? Br J Clin Pharmacol. 2008;65(1):144-6.
19. Pariente A, Grégoire F, Fourrier-Réglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891-8.
20. Uppsala Monitoring Centre. Azithromycin and HMG-CoA reductase inhibitors: rhabdomyolysis. WHO Signal (restricted document). 2008. p. 4-7.